Patents Assigned to Oncorena AB
  • ORELLANINE FORMULATION
    Publication number: 20250387329
    Abstract: A pharmaceutical aqueous solution formulation comprising Orellanine is disclosed.
    Type: Application
    Filed: June 23, 2023
    Publication date: December 25, 2025
    Applicant: ONCORENA AB
    Inventors: Olivier YAMEOGO, Emmanuelle COISSARD, Pal FALCK
  • Treatment of renal cell carcinoma
    Patent number: 9005580
    Abstract: Methods for treating renal cancer by administration of certain 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide compounds, especially 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide (Orellanine), conjugated to an alpha-emitting radionuclide (e.g. Astatine-211) to increase the efficacy of the formulation and/or a large molecule (e.g. a oligomer/polymer such as a PEG or a polysaccharide such as a dextran or a Ficoll®) to reduce the filtration and consequently the renal exposure. Particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods can be used.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: April 14, 2015
    Assignee: Oncorena AB
    Inventors: Borje Haraldsson, Ulf Nilsson, Lisa Buvall, Jenny Nystrom
  • Treatment of Renal Cell Carcinoma
    Publication number: 20130101507
    Abstract: Methods for treating renal cancer by administration of certain 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide compounds, especially 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide (Orellanine), conjugated to an alpha-emitting radionuclide (e.g. Astatine-211) to increase the efficacy of the formulation and/or a large molecule (e.g. a oligomer/polymer such as a PEG or a polysaccharide such as a dextran or a Ficoll®) to reduce the filtration and consequently the renal exposure. Particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods can be used.
    Type: Application
    Filed: March 28, 2011
    Publication date: April 25, 2013
    Applicant: Oncorena AB
    Inventors: Borje Haraldsson, Ulf Nilsson, Lisa Buvall, Jenny Nystrom
  • Treatment of renal cell carcinoma
    Patent number: 8349823
    Abstract: Methods are provided of treating renal cancer by administration of certain 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide compounds, especially 3,3?,4,4?-tetrahydroxy-2,2?-bipyridine-N,N?-dioxide (Orellanine), using particular administration protocols and dosing regimens, as well as pharmaceutical compositions suitable for use in the treatment methods that are provided.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: January 8, 2013
    Assignee: Oncorena AB
    Inventors: Börje Haraldsson, Ulf Nilsson, Lisa Buvall, Jenny Nyström